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n	 INTRODUCTION
Since several years many treatments ince several years many treatments for 
postmenopausal osteoporosis with proven 
efficacy in lowering fracture risk have been 
available. Pharmacological treatment for 
osteoporosis is only indicated when frac-
ture risk is considered unacceptably high 
(1) and it should be continued until the 
fracture risk remains high as just already 
recommended for the management of dia-
betes or blood hypertension. However, for 
osteoporosis the issue appears to be much 
more complicated for a number of reasons. 
Differently from diabetes and hyperten-
sion, drugs for osteoporosis can bring 
persistent structural benefits. For some of 
these drugs, i.e. teriparatide (a drug with 
anabolic properties on bone) the length of 
the treatment was set to 24 months. The 
original rationale of this limited duration 
was linked to concerns on the potential ter-
atogenicity of the drug, but it is also justi-
fied by the risk of favouring bone growth in 
sites where it is not desirable (osteophytes), 
a concern shared also by every anabolic 
drug, included those in development such 
as anti-sclerostin antibodies.
Anti-absorptive drugs (bisphosphonates, 
oestrogens, SERMS and denosumab) reg-
istered for the treatment of postmenopausal 
osteoporosis decrease bone turnover. This 
suppression is associated with increased 
skeletal mineralization and prevention of 
bone loss. The anti-fracture effect is also 
based upon the suppression of turnover 
“per se” (2) which is reverted after treat-
ment discontinuation; from this point of 
view, this would suggest that treatment 
with these drugs should never go beyond 
the effect on bone turnover.
The issue of the treatment duration for an-
ti-reabsorptive drugs arise from the poten-
tial risk related with long-term treatment. 
Thus, the duration of hormone replacement 
therapy is limited by the risk of breast can-
cer and bisphosphonates and denosumab 
for the associated risk of jaw osteomyelitis, 
called also osteonecrosis of the jaw (ONJ) 
and of atypical sub-trochanteric fractures. 
These are extremely rare adverse events 
which do not hamper the positive benefit/
drawback ratio. Treatment discontinuation 
may obviously lead to increased risk of 
fracture within a time-frame which might 
be considerably different among available 
therapies.
In this article we will summarize the avail-
able data concerning the consequences of 
anti-reabsorptive treatment discontinuation 
and then discuss the guidelines to follow, 
referring to the views recently raised by 
NIH in the USA (3).
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SUMMARY
Many treatments for postmenopausal osteoporosis with proven efficacy in lowering fracture risk had become 
available since many years now. In the last few years the issue about treatment duration has become a matter of 
importance. In this paper the pivotal trials for alendronate, risedronate, zoledronate and other anti reabsorptive 
drugs such as denosumab are revised with particular attention to the extension studies aimed to verify the ef-
fect of drug discontinuation. The results of the review highlight differences among the available drugs and the 
practical clinical consequences also in terms of cost-effectiveness. 
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n	 ALENDRONATE: 
 PHASE 3 STUDY
The first phase 3 study with Alendronate 
(ALN) (4) for the treatment of post-meno-
pausal osteoporosis (PMO) included 3 
arms: placebo, ALN 5 mg/day and 10 mg/
die. The placebo arm was abandoned after 
3 years, while patients on ALN continued 
treatment for 2 more years. At the end of 
the fifth year patients on 10 mg/day were 
randomized to continue the treatment or to 
stop it with a 5 additional years of follow-
up (5). BMD increase clearly dissociated 
between the two ALN dosages after the 
first year and for this reason all patients on 
ALN were put on 10 mg/day (6). 
In the patients who took ALN 10 mg/die 
for 10 years, lumbar spine BMD rapidly 
increased after the first year (+5,5%) and 
this was followed by a progressive increase 
of 1.5% per year still well visible at the 
10th year of observation. Femoral BMD 
increased rapidly during the first 2 years 
(about +5%) and this was followed by slight 
increase (about 0.1% per year). In patients 
who discontinued treatment with ALN, 
lumbar spine BMD remained unchanged 
over the 5 years follow-up, but femoral 
BMD decreased within one year since treat-
ment cessation. After 5 years of follow-up 
the mean difference versus baseline in lum-
bar and femoral BMD in the two groups was 
4.8% and 1.8%, respectively (Fig. 1).
For a subset of patients the measurement 
of bone resorption marker (urine NTX) 
and bone formation markers (bone alkaline 
phosphatases or BALP) was available. At 
variance with BMD, bone turnover mark-
ers quickly increased within the first year 
since treatment discontinuation. It is still 
difficult to understand whether bone turn-
over markers returned fully back to basal 
levels considering the effect of supplemen-
tation with calcium and vitamin D which 
were continued in all patients. From the 
data of the placebo group during the first 3 
years while on treatment only with calcium 
and vitamin D it seems that all bone turn-
over markers remain somewhat suppressed 
by 10-20% 5 years after treatment discon-
tinuation. Patients included in the exten-
sion of the study were absolutely insuffi-
cient for any analysis on the consequences 
of treatment cessation on the incidence of 
osteoporotic fractures (Fig. 1).
Figure 1 - Variations of femoral or lumbar spine BMD and of two bone turnover markers (urine 
ntX or bone alkaline phosphatases) in the extension of phase 3 study with alendronate in 
post-menopausal osteoporosis (5).
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Conclusions
the extent of the phase 3 study with ALN 
shows that the cessation of ALN treatment 
is associated with a long-term persistence 
of the positive BMD effects particularly at 
the lumbar spine BMD even if lower than 
those observed in patients who continued 
treatment for 10 years. Bone turnover went 
back to nearly basal levels in 12 months.
n	 ALENDRONATE: FLEX STUDY 
The FIT pivotal trial of ALN for PMO (FIT 
study) (6), included globally 6459 patients 
with only moderate osteoporosis (6-8). For 
the first time an anti-fracture efficacy was 
demonstrated for a treatment based on an 
anti-reabsorptive drug in patients with post-
menopausal osteoporosis (7). Even though 
ALN has been the first drug included in the 
Italian regulation for refound (Nota 79) the 
drugs till offers the best data of effective-
ness on fracture risk (Tab. I). 
The FIT study with the inclusion of a pla-
cebo group was extended for 4 years. Four 
months after the end of the controlled 
trial,approximately one thousand patients 
were randomized to continue treatment 
with 5 or 10 mg/die ALN or placebo in the 
FLEX study (9) with 5 years of additional 
follow up. No relevant differences were 
noted between patients on treatment with 5 
or 10 mg, so the two groups were analysed 
together versus placebo.
In treated patients lumbar spine BMD in-
creased continuously by about 1% per year 
while femoral BMD remained stable or it 
slightly decreased. In the placebo patients 
lumbar spine BMD remained substantially 
stable, while hip BMD decreased to pre-
treatment levels, even though about 10 
years later and when patients were 10 year 
older. At the end of the follow-up for the 
FLEX study the difference between treat-
ed and non-treated patients was 3.8% and 
2.4% for lumbar spine BMD and hip BMD, 
respectively (Fig. 2).
Bone turnover markers remained sup-
pressed in patients who continued treat-
ment while they gradually went back to 
basal levels (pre-FIT) in placebo patients 
(Fig. 2).
Conclusions
The results of the FLEX study related to 
BMD and bone turnover markers are com-
parable with those observed in the phase 3 
study with ALN. After treatment discon-
tinuation bone turnover increased quickly 
within the first 6 months and then more 
slowly with the restoration of the original 
pre-treatment values within 5 years. This 
observation might be of help for identi-
fying, for example, the lag time between 
treatment discontinuation and dental in-
tervention in order to minimize the risk of 
ONJ.
The FLEX study included 662 patients 
treated with ALN and 437 kept on placebo. 
Assuming a fracture incidence of 20% in 
the placebo group, the study had an 80% 
“statistic power” for detecting a difference 
in the fracture risk of 13-33%.
The final results did not show differences 
between the two groups concerning every 
Table I - relative risk reduction (rrr %) for vertebral, non-vertebral and femoral fractures from cochrane 
meta-analysis (alendronate, risedronate and strontium ranelate) or from single pivotal trials (raloxifene, 
basedoxifene) for drugs included in the nota 79. ibandronate has been commercialized at a dose almost 
double than that used in the registrative trials.
Medication RRR vertebral fractures RRR non-vertebral fractures RRR femoral fractures
alendronate 45% 23% 40%
risedronate 39% 20% 26%
ibandronate* 56% 0% 0%
Strontium ranelate 37% 14% 15%
raloxifene 35% 8% (nS) 0
Basedoxifene 42% 9% 0
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Figure 2 - Densitometric and bone turnover marker variations during the Fit study (alendro-
nate in postmenopausal osteoporosis) and its extension in the FleX study. in the FleX study 
patients previously treated with alendronate were randomized to continue alendronate or to 
placebo (9). 
Figure 3 - Fracture incidence in the FleX study, the extension of the Fit study only for previ-
ously treated patients with alendronate (9).
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type of fracture. However a statistically 
55% significant difference was observed 
for clinical vertebral fracture risk, i.e.: the 
fractures diagnosed for the appearance of 
obvious symptoms. The risk of morpho-
metric vertebral fractures was reduced by 
14% (Fig. 3).
Results relative to incidence of non-verte-
bral fractures were re-analysed afterwards, 
dividing patients according to the severity 
of osteoporosis at the moment of inclusion 
in the FLEX study (10). Among patients 
with diagnosis of osteoporosis according to 
the WHO (T score <-2.5), treatment with 
ALN was also associated with a significant 
50% risk reduction of non-vertebral frac-
tures (Fig. 4).
n	 RISEDRONATE: EXTENSION 
 OF THE PIVOTAL TRIALS
The clinical development of Risedronate 
(RIS) included 3 studies. One study was de-
signed to verify the effectiveness on femo-
ral fracture risk (HIP study) (11). The two 
studies with the goal of evaluating vertebral 
fracture risk reduction (VERT studies) were 
conducted one in North America (VERT-
NA) (12) and one in other countries (VERT-
MN) (13). The VERT-NA study included 
a follow-up of one year after 3 years “in 
blind” for RIS 5 mg/die or placebo (14). In 
the active group the cessation of treatment 
was associated with a significant decrease 
within a year of the densitometric values 
to almost pre-treatment values for femoral 
BMD while urine NTX (bone reabsorption 
marker) quickly returned to the values of 
the patients on treatment only with supple-
ments of calcium and vitamin D.
Even if the duration of ALN treatment was 
slightly longer, the difference between the 
two bisphosphonates appears to be quite 
evident. The tail-effect of ALN is about 5 
Figure 4 - relative risk (rr) of non-vertebral 
fractures during FleX study (alendronate 
versus placebo) in patients ranked according 
with femoral neck BMD (t-score) values. in 
patient with persistent osteoporosis (t-score 
<-2.5) prosecution of treatment leads to an 
additional advantage also for non-vertebral 
fractures (10).
Figure 5 - Variation of BMD and urine ntX values during Vern na study and its extension 
(12, 14).
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times longer: the return to pre-treatment 
levels of bone turnover and BMD occurs 
after about one year in patients treated with 
RIS and after about 5 years in those treated 
with ALN for 4 years (Fig. 5).
The extension of VERT-MN study was sig-
nificantly more complex (15). The effect of 
treatment discontinuation was studied in 
patients previously treated for 7 and for 2 
years with RIS. The duration of previous 
treatment was not associated with appre-
ciable differences in term of resolution of 
the effect. The return to pre-treatment val-
ues of femoral neck BMD occurred within 
2 years, while urine NTX levels returned 
to basal levels within 6 months, as for the 
VERT-NA study (Fig. 6).
Conclusions
ALN and RIS clearly differ regarding the 
tail effect in the clinical setting of trials 
differing marginally each-other. It is about 
5 times longer for ALN: the return to pre-
treatment levels of bone turnover and BMD 
occurs after about 1 year in patients treated 
with RIS and 5 years in those treated for 4 
years with ALN. The duration of the treat-
ment with RIS does not affect the duration 
of the tail effect.
n	 ZOLEDRONATE: 
 EXTENSION STUDIES
The original pivotal trial HORIZON with 
Zoledronic Acid (ZOL) versus placebo was 
extended for 3 years (16). The patients in 
the active group received 3 infusions of 
ZOL 4 mg. At the end of this period the 
patients of the active group were random-
ized to continue or not the treatment with 
a 3 years follow-up. Densitometric dif-
ference between the two groups after the 
3 years of follow-up was ca. 1-2% due to 
marginal decrease in femoral neck BMD in 
untreated patients and to constant increases 
of lumbar spine BMD in patients who re-
ceived two additional ZOL infusions (Fig. 
7) (17). During the 3 years of follow-up, 
the two groups were undistinguishable in 
terms of new non-vertebral fractures in-
cidence, while the incidence of vertebral 
fracture was significantly reduced by treat-
ment continuation (Fig. 8) (17). From a re-
cent sub-analysis (18) emerged that in the 
patients who received only one infusion of 
the drug, the reduction of clinical fracture 
risk (of any kind) was equal (-32%) to that 
observed in the patients who received three 
infusions.
Figure 6 - changes in femoral neck BMD and urine ntX in patients of 
Vert-Mn study participating in the extension study. the open circle 
and the black triangle indicate the patients randomized to placebo 
and risedronate respectively, in the first three years of the trial. the 
dashed line indicates the period in which the patients were on pla-
cebo and the continuous line patients when assuming riS (15).
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Conclusions
The tail effect of ZOL appears to be quite 
important and apparently superior to that 
observed with ALN. Also with ZOL treat-
ment discontinuation is associated with a 
partial loss of efficacy on vertebral fracture 
risk but not for non-vertebral fractures. 
n	 EXTENSION OF REGISTRATIVE 
 TRIALS WITH OTHER  
 ANTI-RESORPTIVES
Available data on the tail effect of Iban-
dronate are very few and limited do phase 
2 studies (19). The emerging pattern is a 
clear resemblance with RIS, with the resto-
ration of bone turnover within 6-12 months 
from treatment cessation (Fig. 9). There is 
no tail effect for treatment with estrogens 
and SERMS (Raloxifene and Basedoxi-
fene) since with their discontinuation bone 
turnover returns to basal levels within a 
few weeks and all densitometric increases 
observed during treatment are lost within 
one year (20). The effect of anti-RANKL 
treatment with Denosumab is lost in a few 
weeks both for bone turnover markers and 
for densitometric increase (Fig. 10) (21).
Data regarding the consequences of dis-
continuation of the treatment with Stron-
tium Ranelate are limited and inconclusive 
due to the tiny variations of bone turnover 
markers observed during treatment. The 
densitometric increases observed during 
treatment are related to an undefined effect 
Figure 7 - Densitometric variations in the extension study with ZOl. the patients treated dur-
ing the first three years with ZOl were randomized to continue or not treatment (17).
Figure 8 - Vertebral and non-vertebral fracture incidence in patients in the extension trial with 
ZOl. the patients treated in the first three years with ZOl were randomized to continue (Z6) 
or not (Z3P3) treatment (17).
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of the atomic weight of Strontium (much 
higher than that of calcium) absorbed in the 
bone tissue. This uncertainty is inevitably 
conveyed also to the interpretation of the 
changes in BMD after treatment discon-
tinuation. 
n	 DISCUSSION
The impact of treatment discontinuation in 
postmenopausal osteoporosis varies consid-
erably in relation with the adopted treatment. 
Four distinct scenarios should be considered:
Teriparatide discontinuation
There’s now a very large agreement about 
the need for starting treatment with anti-
reabsorptive drugs soon after the treatment 
course with Teriparatide to save and em-
power the acquired benefits (22, 23).
Denosumab discontinuation
In patients treated with Denosumab, treat-
ment discontinuation is followed by s a re-
bound of bone turnover with an impact on 
fracture risk poorly understood (24). In pa-
tients at very high risk (as those identified 
by the Italian “Nota 79”) (25) it is probably 
appropriate to recommend a therapeutic 
cycle with bisphosphonates immediately 
after Denosumab discontinuation, if a re-
bound in fracture rate is feared.
Estrogens or SERMS discontinuation
After discontinuation of hormones bone 
turnover and BMD return within a few 
weeks to pre-treatment levels. Therefore a 
re-assessment about the opportunity of re-
suming a treatment is warranted.
Figure 10 - BMD and serum ctX variation (bone turnover marker) after discontinuing treat-
ment with denosumab (shadowed area). Serum ctX increases to levels higher than baseline 
(21).
Figure 9 - Bone turnover markers variation 
after ceasing of the treatment with ibandro-
nate (19).
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Ibandronate and risedronate discontinu-
ation
These bisphosphonates have a tail effect 
relatively limited and bone turnover and 
BMD levels return to basal levels within 
a year. If an interruption of the treatment 
is planned (for example for a surgical or a 
dental operation) this should not be extend-
ed over 6 months in patients at high risk of 
fracture.
Alendronate o zoledronate discontinua-
tion
ALN and ZOL are among the drugs with 
the best evidence of reducing the risk of all 
kinds of fracture. They are also the drugs 
with the most persistent tail effect concern-
ing bone turnover, BMD values and frac-
ture risk. The anti-fracture efficacy is par-
tially lost after treatment discontinuation 
for vertebral fractures, while the protection 
is extended for at least 2 years for the risk 
of non-vertebral fractures. Therefore for 
these two drugs it is conceivable to plan 
short discontinuations of the treatment and 
this translates in an additional advantage in 
pharmaco-economic terms.
The issue of the selection of the patients 
candidate for a period of treatment vaca-
tion has recently been addressed by the 
NIH in the USA. As we have seen, with 
treatment discontinuation vertebral frac-
ture risk slightly rises, with a the Relative 
Risk (Fig. 11) rising by 50% for both ALN 
and ZOL versus patients who continue 
treatment. However, the Absolute Reduc-
tion and therefore the NNT (the number of 
patients to treat for preventing a fracture) 
depends on the original risk of fracture. For 
ALN in the whole population included in 
the FLEX trial (9) the NNT was 34. How-
ever, in patients at high risk, such as those 
identified by Nota 79 (previous vertebral or 
femoral fracture or BMD values <-3.0) the 
NNT was merely 17 (Fig. 11). In high risk 
patients (Fig. 4) the prosecution of treat-
ment grants also a significant higher pro-
tection from non-vertebral fractures (10).
These evaluations were at the basis of the 
recommendations recently published by 
NIH(3). Treatment with ALN or ZOL 
may be interrupted after 3-5 years only in 
patients in whom fracture risk is low or 
lowered because of the treatment itself. It 
is recommended to never discontinue treat-
ment in patients with one or more prevalent 
osteoporotic fractures or in whom the BMD 
values are still inferior to -2.5 (T score).
The individuation of the patient in whom it 
is possible to discontinue treatment also de-
pends upon the adherence to the treatment 
itself; i.e.: in patients with a mean adher-
ence in the last 3-5 years inferior to 80%, 
discontinuation is never recommended.
Figure 11 - relative risk reduction (rrr %), absolute risk reduction (arr %) and corre-
sponding number needed to treat (nnt) for vertebral fractures in patients attending the FleX 
trial (9), extension of the Fit trial (6).
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The duration of the interruption should be 
planned on an individual base. In patients 
with a moderate initial fracture risk a reas-
sessment one year after discontinuation is 
appropriate. In patients at high initial risk 
(i.e. with a pre-treatment T score <-3.0) or 
with other risk factors (i.e. corticosteroid 
therapy, smoke, thinness, age >5 years) dis-
continuation should not exceed 8 months 
for ALN and 1-2 years for ZOL (therefore 
2-3 years from last infusion). With most 
anti-reabsorptive treatments, the full anti-
fracture efficacy is achieved within few 
months after commencing therapy (26). 
Treatment prosecution is associated with 
important densitometric increases which 
apparently are not associated with addi-
tional benefits in terms of anti-fracturative 
efficacy. For some drugs (Risedronate and 
Strontium Ranelate) the anti-fracture ef-
ficacy seems even to lessen after the first 
year despite continuous treatment. These 
observations are consistent only with an 
important anti-fracture effect related to 
bone turnover reduction already fully ex-
pressed after few weeks since the start of 
the therapy (27). For this reason it is pref-
erable not to extend the discontinuation for 
more than 6 and 12 months for both RIS 
and ALN. The discontinuation period for 
ZOL is not well established but can exceed 
a year (therefore more than 2 years from 
last infusion).
Final recommendations on the strategies 
to follow for discontinuation of postmeno-
pausal osteoporosis treatment are summa-
rized on the Table II, where the fracture 
risk is esteemed with DeFRA (28, 29).
n	 TREATMENT DURATION 
 AND PHARMACO-ECONOMIC  
 IMPLICATIONS
In Table III are listed the anti-fracture ef-
ficacy data for the most commonly reim-
bursed drugs in Italy. The data are extracted 
from meta-analysis or Health Technical 
Assessments (30) or from pivotal trials 
when these were the only available data. 
Cochrane meta-analysis are available for 
Alendronate, Risedronate and Strontium 
Ranelate (31). For Teriparatide and de-
nosumab only data from the pivotal trials 
were considered. Ibandronate, Raloxifene 
and Basedoxifene were not included in the 
table because there is no evidence of effica-
cy for non-vertebral and femoral fractures.
In a typical population for Nota 79 (11-
13, 32), the 5 years incidence is ca. 30%, 
25% and 7% for vertebral, non-vertebral 
and femoral fractures, respectively. These 
esteems make possible to calculate the re-
duction of the absolute risk (ARR%) and 
therefore the cost for every fracture avoid-
ed assuming a cost per 5 years of treatment 
equal to: Alendronate € 850, Risedronate € 
800, StrontiumRanelate € 3000, Teripara-
tide € 8500 + 500€ for Alendronate for 3-4 
years, Denosumab € 2000.
The cost for avoided fracture is calculat-
ed multiplying the treatment cost for the 
Table II - Final recommendations on the strategies to follow for discontinuation of postmenopausal oste-
oporosis treatment
Drug Fracture Risk DeFRA After-discontinuation recommendations
all drugs >30% (note 79) no discontinuation is advised
Denosumab – Observe a cycle of therapy with bisphosphonates six months after last administration.
estrogens-
SerMS
<20% non pharmacological prevention. reassess after one or two years.
20-30% resume the treatment or alternative treatment (bisphosphonates) after 
two months.
risedronate 
ibandronate
<20% non pharmacological prevention. reassess after six months.
20-30% resume therapy within four months.
alendronate 
Zoledronate
<20% non pharmacological prevention. reassess after one or two years.
20-30% resume treatment within eight-twelve months.
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Table IV - absolute risk reduction (arr%) in a typical note 79 patient for vertebral, non-vertebral and 
femoral fracture (see text for details) and cost to avoid every single fracture.
Drug Vertebral fractures Non-vertebral 
fractures
Femoral fractures Cumulative: 
vertebral x1 + non-
vert x0.5 + femur x2
RRA% Cost
€ x 1000
RRA% Cost
€ x 1000
RRA% Cost
€ x 1000
RRA% Cost
€ x 1000
alendronate 13,5% 6,3 5,75% 14,8 2,8% 30,3 21,7% 3,9
risedronate 11,7% 6,8 5,0% 16,0 1,82% 43,9 17,8% 4,5
Strontium ranelate 11,1% 27,0 3,5% 85,7 1,05% 285,7 15,0% 19,3
teriparatide 19,5% 46,1 13,25% 66,7 2,45% 367,3 31,1% 28,9
Denosumab 20,4% 9,8 5,0% 40,0 2,8% 71,4 28,5 7,0
Table III - relative risk reduction (rrr %) for vertebral, non-vertebral and femoral fractures (see text for 
details).
Drug RRR vertebral fractures RRR non-vertebral fractures RRR femoral fractures
alendronate 45% 23% 40%
risedronate 39% 20% 26%
Zoledronate 70% 24% 40%
Strontium ranelate 37% 14% 15% (nS)
teriparatide 65% 53% 35% (nS)
Denosumab 68% 20% 40%
Figure 12 - cost per fracture avoided in a 5 years period assigning a “therapeutic vacation” 
of 8 months every 5 years to alendronate (for all the other drugs a “tail” effect cannot be at-
tributed).
Number Needed to Treat (NNT for 5years) 
(therefore 100/RRA%) (Tab. IV).
Since a drug reduces all three kinds of frac-
ture all together, a cost for an arbitrary mix 
was generated assuming the cost of femo-
ral fracture equal to the cost of 2 vertebral 
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fractures and the cost of a non-vertebral 
fracturehalf of that of a vertebral fracture.
As we have seen, in a vast proportion of 
patients, a treatment with an adequate ad-
herence to ALN and ZOL allows a treat-
ment “vacation” every 5 years without 
consequences on fracture risk. This lowers 
the cost for fracture avoided with ALN for 
an additional 18% (Fig. 12). For all these 
esteems ZOL was not included since it is 
administered only in Hospitals, but the 
cost-effectiveness is very similar to that es-
teemed for Alendronate.
n	 SUMMARIZING CONCLUSIONS
The pharmacological treatment for post-
menopausal osteoporosis is justified only 
for patients at very high risk of fracture. 
This can now be easily esteemed with 
FRAX or DEFRA (27). After a few years 
of treatment the risk is likely to decrease 
and a treatment vacation might be taken 
into account, but the supplementation with 
calcium and vitamin D and the removal of 
risk factors should continue.
The decision of discontinuing the treat-
ment depends on the drug used and on the 
re-assessment of fracture risk after at least 
3-5 years of treatment. A treatment course 
with Teriparatide must always be followed 
by therapy with anti-reabsorptive (e.g.: 
bisphosphonates). Denosumab should 
never be discontinued and, if that occurs, 
a treatment course with bisphosphonates 
should be considered in order to prevent 
the rebound of bone turnover. Discontinu-
ation of estrogens, Raloxifene, Basedoxi-
fene, Risedronate and Ibandronate is asso-
ciated with the quick loss of the acquired 
benefits, and therefore the discontinuation 
should never exceed 6 months.
Treatment with ALN and ZOL is charac-
terized by an important “tail effect”. Thus, 
after 5 years of optimal adherence, a treat-
ment discontinuation might be planned in 
low-risk patients (<30% according to De-
FRA), but not in patients with previous se-
vere fractures or in whom the risk remains 
high even after years of treatment (Fig. 13).
The possibility of implementing “treatment 
vacations” increases the cost-effectiveness 
profile for ALN and ZOL making these 
therapies of Nota 79 really cost-effective; 
i.e. the cost of treatment in the framework 
of the Nota 79 is now lower than the hospi-
tal costs for the same fracture!
Figure 13 - Flow chart of the behavior to follow concerning the duration of treatment with 
alendronate.
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